This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'

By: Adam Feuerstein | 03/25/14 - 02:35 PM EDT

Stocks in this article: GERNCLDXCYTRNLNKRPTPNVAXORMPAGENGALE

A list that might be interesting only to me, but I will share anyway: The biotech and drug stocks getting hit the hardest during the biotech correction -- or whatever you want to call it: 

Tops on the list is Geron (GERN), down 58% in March.

GERN Chart
GERN data by YCharts

Geron shares slid following the FDA's decision to place its lead drug imetelstat on clinical hold due to safety concerns, so it's not fair to blame the market weakness in March for its woes. 

At No. 2: Ceres (CERE), an agriculturial biotech company, down 37%. I don't think anyone cares about Ceres. My apologies if you do. 

A trio of stocks tied in third place: Xoma (XOMA), Cytrx (CYTR) and Celldex Therapeutics (CLDX) have all lost 39% of their value in March. 

Cytrx's entanglement in a messy stock promotion scandal with the specter of an SEC investigation hovering of the stock easily explains the sell off. Xoma also issued some negative clinical data early in the month. 

Celldex is a bit tougher to figure out. 

CLDX Chart
CLDX data by YCharts

Celldex has benefitted from inclusion in the "immuno-oncology" investing craze, so perhaps the selling we're seeing here is an unwinding of a biotech buzzword trade. 

Next: NewLink Genetics (NLNK) and Raptor Pharmaceuticals (RPTP) both down 37% in March. 

NewLink is another over-valued cancer buzzword stock which is finally reverting back to the mean. Raptor is proof that orphan-drug disease stocks aren't all gravity proof, especially when you provide disappointing 2014 sales guidance. 

Other notably weak biotech and drug stocks in March: Agenus (AGEN) (-33%), Galena Biopharma (GALE) (-32%), Zogenix (ZGNX) (-32%), Novavax (NVAX) (-34%) and Oramed Pharmaceuticals (ORMP) (-27%). The reasons for weakness in most of these should be self-evident.



Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.

Markets

DOW 16,765.34 +87.44 0.52%
S&P 500 1,959.70 +8.88 0.46%
NASDAQ 4,470.4480 +17.6560 0.40%

Adam's Tweets

Brokerage Partners

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs